GHRH analogue
A growth-hormone-releasing factor analogue, approved overseas for a defined HIV-related indication.
Tesamorelin has clinical trial support for its specific approved indication (HIV-associated lipodystrophy). That evidence does not transfer to general anti-ageing or fat-loss marketing.
In its approved clinical use, side effects are monitored by a specialist. Outside that indication, it carries the same hormonal and sourcing concerns as other unapproved use.
Specialist-led access in Australia, tightly scoped to its approved indication.
Access is specialist-led and tied to the defined indication, not a general wellness pathway.
This entry is general information about Tesamorelin, not a recommendation to use it. We don’t provide dosing, protocols or sourcing. Speak to a registered practitioner.
This is general education, not medical advice. Peptides.au does not sell, supply, recommend or promote any product or clinic. Always speak with a registered Australian health practitioner before making any health decision.